Generic Pharmaceuticals Businesses for Sale in Una

• Established pharmaceutical formulation manufacturing unit located in Una district, Himachal Pradesh. • Operates from a built-up facility of approximately 21,000 sq. ft. across two floors. • Infrastructure is expandable up to double the existing built-up area. • Separate, dedicated production blocks for general formulations and beta-lactam formulations. • Manufactures tablets, capsules, liquids, ointments, and dry syrups. • Licensed to manufacture approximately 1,000 formulations across multiple therapeutic segments. • Product portfolio spans general, diabetic care, neuro-psychiatry, nephrology, gynaecology, orthopaedic, pediatric, and other specialities. • No NSQ (Not of Standard Quality) record for any product to date. • Installed annual capacity supports turnover of INR 50–60 crore in a single shift. • Currently operates at around 25% capacity with an annual turnover of INR 12–14 crore. • Over 80% of revenue is generated through third-party manufacturing contracts. • Maintains strong working capital discipline with 100% debtor recovery within 60 days. • Enjoys favourable creditor terms with approximately 90-day payment cycles. • Equipped with a fully functional in-house Quality Control laboratory. • QC facilities include chemical, instrumental, and microbiological testing along with stability study instruments. • Offers significant growth potential with up to threefold scale-up through higher capacity utilization. • Holds GMP and GLP certifications compliant with revised Schedule M standards. Does not hold USFDA approval.

• Established pharmaceutical formulation manufacturing unit located in Una district, Himachal Pradesh. • Operates from a built-up facility of approximately 21,000 sq. ft. across two floors. • Infrastructure is expandable up to double the existing built-up area. • Separate, dedicated production blocks for general formulations and beta-lactam formulations. • Manufactures tablets, capsules, liquids, ointments, and dry syrups. • Licensed to manufacture approximately 1,000 formulations across multiple therapeutic segments. • Product portfolio spans general, diabetic care, neuro-psychiatry, nephrology, gynaecology, orthopaedic, pediatric, and other specialities. • No NSQ (Not of Standard Quality) record for any product to date. • Installed annual capacity supports turnover of INR 50–60 crore in a single shift. • Currently operates at around 25% capacity with an annual turnover of INR 12–14 crore. • Over 80% of revenue is generated through third-party manufacturing contracts. • Maintains strong working capital discipline with 100% debtor recovery within 60 days. • Enjoys favourable creditor terms with approximately 90-day payment cycles. • Equipped with a fully functional in-house Quality Control laboratory. • QC facilities include chemical, instrumental, and microbiological testing along with stability study instruments. • Offers significant growth potential with up to threefold scale-up through higher capacity utilization. • Holds GMP and GLP certifications compliant with revised Schedule M standards. Does not hold USFDA approval.